Welcome to our dedicated page for NuVasive news (Ticker: NUVA), a resource for investors and traders seeking the latest updates and insights on NuVasive stock.
NuVasive, Inc. (NASDAQ: NUVA) is a leader in spine technology innovation, dedicated to transforming spine surgery with minimally disruptive, procedurally integrated solutions. Headquartered in San Diego, NuVasive aims to advance surgical care and improve patient outcomes through its extensive product portfolio and global reach.
The company’s core offerings include surgical access instruments, spinal implants, fixation systems, biologics, and software for surgical planning. NuVasive also provides navigation and imaging solutions, magnetically adjustable implant systems for both spine and orthopedics, and intraoperative neuromonitoring technology and services. With an emphasis on speed of innovation, NuVasive continually develops new products to meet the evolving needs of spine surgeons, hospitals, and patients.
NuVasive has shown robust financial performance, with over $1 billion in net sales and operations in more than 50 countries. The company's recent achievements include a 2.4% increase in total net sales for the second quarter of 2023, reaching $317.8 million. This growth is driven by the adoption of new products and higher procedural volumes in the U.S.
The company is on the path to combining with Globus Medical, which is anticipated to drive further value creation for shareholders and expand its impact on improving patient lives globally. This merger is expected to enhance NuVasive's ability to deliver innovative and clinically proven outcomes.
NuVasive also emphasizes corporate social responsibility through initiatives like the NuVasive Spine Foundation®, which provides life-changing spinal surgery to disadvantaged communities, and other patient-to-patient support programs.
For more information, visit www.nuvasive.com.
NuVasive (NASDAQ: NUVA) announced an expanded partnership with the International Spine Study Group Foundation (ISSGF) to initiate two new clinical studies aimed at enhancing patient outcomes in adult spinal deformity surgery. The studies will evaluate minimally invasive surgical techniques and the performance of NuVasive's VersaTie® fixation system. This collaboration builds on a previous five-year study, reinforcing NuVasive's commitment to clinical innovation. The partnership aims to inform better surgical practices and improve patient care through rigorous data collection.
NuVasive, a leader in spine technology, reported Q4 and full year 2020 results reflecting impacts from COVID-19. Q4 net sales decreased by 6.0% to $291.8 million, while full year sales fell 10.1% to $1.051 billion. The company experienced a GAAP diluted loss of $0.72 per share for 2020, compared to a profit of $1.23 per share in 2019. Non-GAAP figures showed a diluted EPS of $0.59 for Q4 and $1.23 for the year. Cash and investments totaled $1.030 billion as of Dec. 31, 2020. Additionally, NuVasive acquired Simplify Medical to enhance their C360 portfolio.
NuVasive, Inc. (NASDAQ: NUVA) announced its acquisition of Simplify Medical, a developer of the Simplify Cervical Artificial Disc, for $150 million, enhancing its cervical portfolio in a $2.6 billion market. The Simplify Disc is clinically superior to traditional alternatives and is supported by FDA studies. This acquisition aims to broaden NuVasive's offerings in the cervical spine segment, allowing access to comprehensive solutions for surgical procedures. The deal is expected to drive net sales growth and be accretive to earnings in 2022, reflecting positive financial outlooks for NuVasive.
NuVasive, Inc. (NASDAQ: NUVA), a leader in spine technology innovation, announced its participation in the 41st Annual Cowen Health Care Conference on March 1, 2021, at 11:40 a.m. ET. The presentation will be available via live webcast on their Investor Relations page. NuVasive focuses on minimally disruptive surgical solutions, aiming to enhance surgical outcomes and improve patient care. The company boasts over $1 billion in net sales and operates in more than 50 countries, serving healthcare professionals and patients alike.
NuVasive, Inc. (NASDAQ: NUVA) will release its fourth quarter and full year 2020 earnings results on February 25, 2021, after market close. A conference call will occur at 4:30 p.m. ET to discuss the financial performance. Domestic callers can dial 1-800-954-0604, while international callers can use 1-312-281-1210. The call will be available for replay until March 4, 2021. NuVasive focuses on minimally invasive spine technology, boasting over $1 billion in net sales and operations in more than 50 countries.
NuVasive, Inc. (NASDAQ: NUVA) announced the opening of a new East Coast Experience Center in Englewood, New Jersey, planned for Q3 2021. This facility expands the Clinical Professional Development (CPD) program, which aims to enhance surgeon education in minimally invasive spine surgery. The center will feature advanced training capabilities, including cadaveric labs and virtual education technologies. This expansion reflects NuVasive's commitment to improving patient outcomes through better training, following the successful establishment of a West Coast Experience Center in San Diego.
NuVasive (NASDAQ: NUVA) has appointed Dr. Siddhartha Kadia to its Board of Directors as of February 1, 2021. Dr. Kadia brings over 20 years of experience in medical technology, notably as former CEO of EAG Laboratories, acquired for $780 million in 2017. His expertise includes marketing and operations with Life Technologies, overseeing a $2 billion product portfolio. CEO Christopher Barry emphasizes Dr. Kadia's leadership in innovation and growth as valuable for advancing NuVasive's mission to transform surgery and improve patient outcomes. Dr. Kadia aims to enhance NuVasive's long-term strategy and shareholder value.
NuVasive (NASDAQ: NUVA), a leader in spine technology, announced it will present at the 23rd Annual Needham Virtual Growth Conference on January 14, 2021, at 1:15 p.m. ET. The presentation aims to highlight the company's innovative, minimally disruptive solutions for spine surgery.
A live webcast will be accessible on the Investor Relations page of the company's website, with a replay available for 30 days post-event. NuVasive, with over $1 billion in net sales and operations in over 50 countries, focuses on advancing surgical care.
NuVasive, Inc. (NASDAQ: NUVA) announced the results of a comprehensive study published in The Spine Journal, highlighting the advantages of single-position spine surgery. The multi-center study involved 390 patients and compared anterior lumbar interbody fusion (ALIF) and lateral lumbar interbody fusion (LLIF) methods. Key findings showed that single-position lateral surgery (SPLS) significantly reduced operating time by over three hours, lowered blood loss, and shortened hospitalization by an average of two days, while minimizing postoperative complications.
NuVasive, Inc. (NASDAQ: NUVA), a leader in spine technology innovation, announced that CEO J. Christopher Barry will present at the 39th Annual Virtual J.P. Morgan Healthcare Conference on January 13, 2021, at 2:50 p.m. ET. A live webcast will be available on the company's Investor Relations page, with a replay accessible for 30 days after the event. NuVasive focuses on less invasive surgical solutions and aims to enhance patient care, with over $1 billion in net sales and operations in more than 50 countries.
FAQ
What is the market cap of NuVasive (NUVA)?
What does NuVasive, Inc. specialize in?
Where is NuVasive headquartered?
What are some of NuVasive's core products?
How did NuVasive perform in the second quarter of 2023?
Is NuVasive involved in any mergers or acquisitions?
How does NuVasive contribute to social responsibility?
What is the mission of NuVasive, Inc.?
In how many countries does NuVasive operate?
What recent financial milestone has NuVasive achieved?
Where can I find more information about NuVasive?
